EWTX Edgewise Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Edgewise Therapeutics, Inc. (EWTX)

Liquidity shortages and the depletion of reserves due to R&D expenditures are creating financial pressure on Edgewise Therapeutics (EWTX). The GURU.Markets platform reports quarterly earnings per share (EPS) growth, where 2608.80 serves as the current metric. Partnerships with medical centers treating skeletal pathologies and the company's status as an innovator in developing small molecules for muscle protection provide positive momentum.

Edgewise Therapeutics, Inc. (EWTX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Edgewise Therapeutics

- share price and consensus valuation forecast:
Fundamental company analysis:edgewisetx.com, EWTX
Manufactured product of Edgewise Corp

Investors often face the challenge of the market misperceiving a company's interim results. The reduction of capital expenditures through the outsourcing of clinical trials and manufacturing at Edgewise Therapeutics (EWTX) stabilizes the operating base. This indicator measures the rate of change in earnings per share, eliminating information gaps between reports. By analyzing the quarterly EPS trend, one can identify the risk of overpaying during sharp peaks, which allows for the precise calibration of the entry point into the asset.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata